Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany
Autor: | Erin Zagadailov, Paul J Bröckelmann, Brian Seal, Timothy M Illidge, Courtney Johnson, Viktor V. Chirikov, Shelby Corman, Cynthia Macahilig, Mehul Dalal |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2018 |
Předmět: |
Oncology
Male Cancer Research Immunoconjugates medicine.medical_treatment chemotherapy 0302 clinical medicine Autologous stem-cell transplantation Recurrence Germany Antineoplastic Combined Chemotherapy Protocols Brentuximab vedotin Brentuximab Vedotin Manchester Cancer Research Centre Hematopoietic Stem Cell Transplantation Hematology Hodgkin Disease humanities Treatment Outcome 030220 oncology & carcinogenesis Retreatment Female Stem cell autologous stem cell transplant medicine.drug medicine.medical_specialty Transplantation Autologous Relapsed 03 medical and health sciences brentuximab vedotin Internal medicine medicine Refractory Hodgkin Lymphoma Humans In patient Progression-free survival Retrospective Studies Postoperative Care Chemotherapy business.industry ResearchInstitutes_Networks_Beacons/mcrc Retrospective cohort study Survival Analysis United Kingdom Surgery body regions Drug Resistance Neoplasm refractory Hodgkin lymphoma business progression-free survival 030215 immunology |
Zdroj: | Zagadailov, E A, Corman, S, Chirikov, V, Johnson, C, Macahilig, C, Seal, B, Dalal, M R, Broeckelmann, P J & Illidge, T 2018, ' Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany ', Leukemia and Lymphoma, vol. 59, no. 6, pp. 1413-1419 . https://doi.org/10.1080/10428194.2017.1382698 Zagadailov, E A, Corman, S, Chirikov, V, Johnson, C, Macahilig, C, Seal, B, Dalal, M R, Broeckelmann, P J & Illidge, T 2018, ' Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany ' Leukemia & lymphoma, vol 59, no. 6, pp. 1413-1419 . DOI: 10.1080/10428194.2017.1382698 |
Popis: | This retrospective study compared effectiveness of (brentuximab vedotin) BV to other chemotherapies in patients with rrHL following an autologous stem cell transplant (ASCT). Data originated from a medical chart review of patients treated in real-world clinical settings at 50 sites in the United Kingdom and Germany. Inverse probability of treatment weights based on propensity scores were used to adjust for differences in baseline characteristics between treatment groups. Among 312 rrHL patients included, 196 received BV and 116 received physicians' choice chemotherapy. Median PFS was significantly longer (27.0 months vs. 13.4 months; p = .0144) and 12-month OS survival greater (78.1% vs. 65.9%; p = .0129) with BV compared to chemotherapy. Documented adverse events included leukopenia (12.8%) and peripheral neuropathy (8.7%) for BV and leukopenia (12.1%), anemia (5.2%) and diarrhea (5.2%) for chemotherapy. In this real-world study, rrHL patients treated for relapse after ASCT with BV had longer median PFS and 12-month OS than patients receiving chemotherapy. |
Databáze: | OpenAIRE |
Externí odkaz: |